Search This Blog

Monday, January 24, 2022

U.S. FDA declines to approve Merck's cough treatment

 Merck & Co said on Monday the U.S. Food and Drug Administration declined to approve its experimental drug for the treatment of chronic cough and sought additional information on the treatment's effectiveness.

Merck said it would meet with the agency to discuss next steps on the oral drug, gefapixant.

https://finance.yahoo.com/news/u-fda-declines-approve-mercks-115310497.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.